Introduction & Objective: Missing doses in people living with diabetes (PLWD) who use multiple daily insulin injections may lead to inadequate glycemic control. This real-world study assessed the probability of and influencing factors for missed bolus insulin injections in PLWD.

Methods: Data from 21 countries were collected from 22 964 adults with T1D or T2D using CGM and a smart pen (NovoPen 6 or NovoPen Echo Plus) to deliver bolus insulin (2 559 118 CGM and injection days [111 days/adult]). The daily probability of missing ≥ 1 bolus dose (no bolus dose within −15 to +60 mins from meal onset detected by the GRID algorithm) was estimated by a generalized linear mixed model based on logistic regression. Data upload frequency (pen to app) was used as a proxy for smart pen engagement.

Results: The mean probability of having a day with ≥ 1 missed bolus dose was 44.5% (95% CI: 44.1-45.0%), which decreased with increasing age (Figure A) and smart pen data upload frequency (not shown). The probability of having a day with ≥ 1 missed bolus dose was highest on Fridays and Saturdays (Figure B). On any given day, the probability of missing a bolus dose at breakfast, lunch, dinner or snack was 7.5%, 12.2%, 11.1% and 19.4%, respectively.

Conclusion: Bolus insulin adherence increased with age and smart pen engagement and decreased on weekends. Smart insulin pen data can provide novel insights into individuals’ real-world injection behaviors.

Disclosure

F. Ampudia Blasco: Advisory Panel; Novo Nordisk, Sanofi. Speaker's Bureau; Lilly Diabetes. Advisory Panel; Roche Diagnostics, Bayer Inc. M.L. Jensen: Employee; Novo Nordisk. A. Kaas: Employee; Novo Nordisk A/S. Stock/Shareholder; Novo Nordisk A/S. N.N. Knudsen: Employee; Novo Nordisk. Stock/Shareholder; Novo Nordisk. R. Nishimura: Speaker's Bureau; Abbott. Advisory Panel; Abbott Japan Co., Ltd. Speaker's Bureau; Boehringer-Ingelheim, Mitsubishi Tanabe Pharma Corporation, Kowa Company, Ltd., Medtronic, Sanofi, Taiho Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co., Ltd., Teijin Pharma Limited, Eli Lilly and Company, Novo Nordisk A/S. Consultant; Terumo Corporation.

Funding

Novo Nordisk A/S

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.